• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Biologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab.

作者信息

Gargiulo Luigi, Toso Francesco, Ibba Luciano, Valenti Mario, Costanzo Antonio, Narcisi Alessandra

机构信息

Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy.

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy.

出版信息

Dermatol Pract Concept. 2023 Apr 1;13(2). doi: 10.5826/dpc.1302a103.

DOI:10.5826/dpc.1302a103
PMID:37196286
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10188160/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7eca/10188160/2c40a623e024/dp1302a103g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7eca/10188160/83c9dbfc4f06/dp1302a103g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7eca/10188160/2c40a623e024/dp1302a103g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7eca/10188160/83c9dbfc4f06/dp1302a103g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7eca/10188160/2c40a623e024/dp1302a103g002.jpg

相似文献

1
Biologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab.用于治疗Hallopeau连续性肢端皮炎的生物制剂：两例使用司库奇尤单抗和优特克单抗成功治疗的病例报告
Dermatol Pract Concept. 2023 Apr 1;13(2). doi: 10.5826/dpc.1302a103.
2
Acrodermatitis continua of Hallopeau with insufficient response to ixekizumab and infliximab, successfully treated with a combination of ustekinumab and tofacitinib.对喜克索单抗和英夫利昔单抗反应不足的Hallopeau连续性肢端皮炎，采用优特克单抗和托法替布联合治疗成功治愈。
Eur J Dermatol. 2023 Apr 1;33(2):182-183. doi: 10.1684/ejd.2023.4461.
3
Treatment of acrodermatitis continua of hallopeau with ixekizumab.以依奇珠单抗治疗 Hallopeau 连续性肢端皮炎。
J Dermatolog Treat. 2021 Feb;32(1):117-119. doi: 10.1080/09546634.2019.1628170. Epub 2019 Jul 5.
4
Acrodermatitis continua of hallopeau successfully treated with adalimumab.用阿达木单抗成功治疗的Hallopeau连续性肢端皮炎。
J Clin Aesthet Dermatol. 2012 Feb;5(2):60-2.
5
Ustekinumab for the treatment of acrodermatitis continua of Hallopeau refractory to anti-TNF agents.优特克单抗用于治疗对抗肿瘤坏死因子药物难治的Hallopeau连续性肢端皮炎。
Dermatol Ther. 2017 Mar;30(2). doi: 10.1111/dth.12460. Epub 2017 Jan 30.
6
Acrodermatitis continua of Hallopeau successfully treated with bimekizumab: A case report.用比美吉珠单抗成功治疗的哈洛佩奥连续性肢端皮炎：一例报告
SAGE Open Med Case Rep. 2023 Mar 21;11:2050313X231160937. doi: 10.1177/2050313X231160937. eCollection 2023.
7
Acrodermatitis continua of Hallopeau successfully treated with secukinumab.司库奇尤单抗成功治疗Hallopeau连续性肢端皮炎。
J Dermatolog Treat. 2018;29(sup1):3-5. doi: 10.1080/09546634.2018.1527993.
8
The Use of Biologic Therapy in the Treatment of Acrodermatitis Continua of Hallopeau: A Review.生物疗法在 Hallopeau 连续性肢端皮炎治疗中的应用：综述。
J Cutan Med Surg. 2019 Jul/Aug;23(4):428-435. doi: 10.1177/1203475419836435. Epub 2019 Apr 2.
9
Acrodermatitis continua of Hallopeau treated successfully with ustekinumab and acitretin after failure of tumour necrosis factor blockade and anakinra.肿瘤坏死因子阻断治疗及阿那白滞素治疗失败后，用乌司奴单抗和阿维A成功治疗的Hallopeau连续性肢端皮炎。
Dermatology. 2015;230(2):97-100. doi: 10.1159/000367690. Epub 2014 Nov 27.
10
Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau.肿瘤坏死因子阻滞剂及优特克单抗治疗掌跖脓疱病和Hallopeau连续性肢端皮炎的疗效及安全性
J Eur Acad Dermatol Venereol. 2020 Oct;34(10):2330-2338. doi: 10.1111/jdv.16265. Epub 2020 Mar 30.

引用本文的文献

1
Acrodermatitis continua of Hallopeau: a review and update on biological and small molecule targeted immunomodulatory therapies.哈洛佩奥连续性肢端皮炎：生物和小分子靶向免疫调节疗法的综述与更新
Front Immunol. 2025 Aug 15;16:1525821. doi: 10.3389/fimmu.2025.1525821. eCollection 2025.

本文引用的文献

1
Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study.抗白介素 17 和抗白介素 23 生物药物治疗头皮银屑病：单中心回顾性对比研究。
Dermatol Ther. 2022 Feb;35(2):e15228. doi: 10.1111/dth.15228. Epub 2021 Nov 30.
2
Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau.肿瘤坏死因子阻滞剂及优特克单抗治疗掌跖脓疱病和Hallopeau连续性肢端皮炎的疗效及安全性
J Eur Acad Dermatol Venereol. 2020 Oct;34(10):2330-2338. doi: 10.1111/jdv.16265. Epub 2020 Mar 30.
3
Treatment of acrodermatitis continua of hallopeau with ixekizumab.
以依奇珠单抗治疗 Hallopeau 连续性肢端皮炎。
J Dermatolog Treat. 2021 Feb;32(1):117-119. doi: 10.1080/09546634.2019.1628170. Epub 2019 Jul 5.
4
The Use of Biologic Therapy in the Treatment of Acrodermatitis Continua of Hallopeau: A Review.生物疗法在 Hallopeau 连续性肢端皮炎治疗中的应用：综述。
J Cutan Med Surg. 2019 Jul/Aug;23(4):428-435. doi: 10.1177/1203475419836435. Epub 2019 Apr 2.
5
European consensus statement on phenotypes of pustular psoriasis.欧洲脓疱型银屑病表型共识声明。
J Eur Acad Dermatol Venereol. 2017 Nov;31(11):1792-1799. doi: 10.1111/jdv.14386. Epub 2017 Aug 29.